ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0680

Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study

Johanne LIBERATORE1, Yann Nguyen2, Jerome HADJADJ3, Pascal Cohen4, Luc Mouthon5, Xavier Puéchal6, Loic Guillevin7 and Benjamin Terrier8, 1Centre Hospitalier ANGOULEME, Angouleme, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3Cochin Hospital, Paris, France, 4CHU Cochin, Paris, France, 5Hopital Cochin - Paris University, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7University Paris Descartes, Paris, France, 8Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Infection

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels during RTX and its association with the risk of relapse and serious infection is of interest.

Methods: We conducted a retrospective single-centre cohort study including patients with granulomatosis with polyangiitis and microscopic polyangiitis who received RTX maintenance therapy between January 2010 and November 2022. Gammaglobulin levels were measured before induction therapy (month -6), at initiation of RTX maintenance therapy (month 0) and every 6 months during maintenance therapy. Patients were categorized into several groups: (1) patients with gammaglobulin levels < 6 g/L at initiation month 0; (2) patients with gammaglobulin decline between induction and initiation of maintenance therapy >25%; and finally (3) patients responding to both criteria simultaneously. Our primary objective was to assess the impact of gammaglobulin decline on the risk of vasculitis relapse and serious infections.

Results: We included 98 patients, all of whom fulfilled the ACR/EULAR classification criteria of AAV. The median gammaglobulin level at initiation of induction therapy was 10.4 g/L (IQR 8.4–12.9) and it significantly decreased to 7.5 g/L (5.9-8.8) at initiation of maintenance therapy with a median decrease of -25% (IQR -13.8 – -42.4). Gammaglobulin levels remained stable throughout follow-up (Figure 1). Factors associated with gammaglobulin level decline >25% and gammaglobulin level < 6 g/L after induction were age > 60 years (OR 4.1; 95%CI 1.2–14.7), baseline gammaglobulin levels < 10 g/L (OR 5.9; 95%CI 1.7–25.4) and use of pulses of methylprednisolone at induction (OR 4.7; 95%CI 1.4–2). Gammaglobulin decline was not associated with the risk of relapse. In contrast, serious infection-free survival was significantly poorer in patients with both gammaglobulin < 6 g/L and gammaglobulin decline >25% (adjusted HR 2.3; 95%CI 1.0–5.1) (Figure 2) and in those who received pulses of methylprednisolone (HR 5.6; 95%CI 2.3–13.4) (Table 1).

Conclusion: Older age, low gammaglobulin levels and pulses of methylprednisolone at induction are associated with greater gammaglobulin decline after induction. Although it is not associated with a lower risk of vasculitis relapse, gammaglobulin decline is associated with an increased risk of serious infections.

Supporting image 1

Table 1. Odds ratios (95% CI) for the risk of severe infection (N=98)

Supporting image 2

Figure 1. Evolution of gammaglobulin levels after induction and maintenance therapy with RTX. Panel A shows the evolution of gammaglobulin levels after induction and maintenance therapy for the whole population (N=98). Panel B shows the evolution of gammaglobulin levels after induction and maintenance therapy comparing the group with or without both gammaglobulin decrease >25% and gammaglobulin level <6 g/L.

Supporting image 3

Figure 2. Kaplan–Meier plots of the risk of vasculitis relapse, major relapse and severe infections. Panel A shows the time to the first relapse according to gammaglobulin decline and gammaglobulin level at month 0. Panel B shows the time to the first major relapse according to gammaglobulin decline and gammaglobulin level at month 0. Panel C shows the time to the first severe infection according to gammaglobulins decline and gammaglobulin level at month 0.


Disclosures: J. LIBERATORE: None; Y. Nguyen: None; J. HADJADJ: None; P. Cohen: None; L. Mouthon: None; X. Puéchal: None; L. Guillevin: None; B. Terrier: AstraZeneca, 5, CSL Vifor, 2, GlaxoSmithKlein(GSK), 2.

To cite this abstract in AMA style:

LIBERATORE J, Nguyen Y, HADJADJ J, Cohen P, Mouthon L, Puéchal X, Guillevin L, Terrier B. Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-factors-for-hypogammaglobulinemia-and-association-with-relapse-and-severe-infections-in-anca-associated-vasculitis-a-retrospective-single-centre-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-hypogammaglobulinemia-and-association-with-relapse-and-severe-infections-in-anca-associated-vasculitis-a-retrospective-single-centre-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology